Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06489301

Mechanisms for Laser-Induced Rejuvenation

It has shown that laser wounding of geriatric skin protects it against skin cancer. The purpose of this study is to determine the origin of cells called fibroblasts which are present after treatment with Fractionated Laser Resurfacing (FLR). These cells restore a youth-like ultraviolet B (UVB) response, but where they come from is currently unknown. The study recruits subjects who are scheduled to undergo abdominoplasties to investigate the origin of those cells stimulated by laser treatment.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Skin Cancer Neoplasms Neoplasms by Site Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Pharmacology Translational Unit

Fairborn, Ohio, 45324, United States

Location status: Recruiting

Location contact

Pharmacology Translational Unit

CONTACT

[email protected]

937-245-7500

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult males and females 18 and older
  • Able to comprehend procedures and risks
  • Planning to undergo abdominoplasty surgery
  • Minimum amount of skin to be removed is 50 x 20cm

Exclusion criteria

  • Medical history of not well-controlled diabetes. This is defined as a subject who needs high doses of insulin, recent history of hospitalization for diabetes-related complications, or poor wound health as evidenced by diabetic ulcers. Subjects who have been deemed healthy enough for abdominoplasty surgery would tend to suggest that their diabetes should not be an issue. However, if the subjects have diabetic complications as outlined above, they could affect the wound healing which is the object of this protocol so they would be excluded.
  • Pregnant or nursing
  • History of pathologically abnormal wound healing such as keloidal scars
  • Existing tattoos on the abdomen that are so extensive that they could interfere with the study

Treatment and study plan

Fractionated Laser Resurfacing

Device

A rejuvenating laser that makes tiny holes in the very superficial part of the skin.

Primary outcomes

  1. To test if the new fibroblasts that develop in response to fractionated laser resurfacing (FLR) wounding are derived from blood-derived monocytes.

    Time frame: 2 weeks prior to skin removal and 1 week prior to skin removal

    Identify cells in the skin that have been wounded by FLR at 2 weeks and 1 week previously, for cells that co-express markers for both fibroblasts and monocytes by using single cell RNA-sequencing

  2. To test if possible cells transitioning from monocytes to fibroblasts are found in the top part of the dermis (papillary dermis).

    Time frame: 2 weeks prior to skin removal and 1 week prior to skin removal

    Using tissue RNA-seq, PI will define if co-expressing cells are in the papillary dermis.

Secondary outcomes

  1. To define the number and types of cells populating the skin following fractionated laser resurfacing (FLR) wounding

    Time frame: 2 weeks prior to skin removal and 1 week prior to skin removal

    Define the number and types of cells following FLR wounding at 2 weeks and 1 week prior to skin removal by using single-cell RNA-seq.

  2. To define the locations of the number of cells populating in the skin following fractionated laser resurfacing (FLR) wounding

    Time frame: 2 weeks prior to skin removal and 1 week prior to skin removal

    Define the locations of the number cell following FLR wounding at 2 weeks and 1 week prior to skin removal by using tissue RNA-seq.

  3. To define the locations of the types of cells populating in the skin following fractionated laser resurfacing (FLR) wounding

    Time frame: 2 weeks prior to skin removal and 1 week prior to skin removal

    Define the locations of the different cell types following FLR wounding at 2 weeks and 1 week prior to skin removal by using tissue RNA-seq.

Study contacts

Contact information is provided by the study sponsor or research team.

Manager, Clinical Research Operations

CONTACT

[email protected]

937-245-7500

Regulatory Specialist

CONTACT

[email protected]

937-245-7500

Sponsors and collaborators

Lead sponsor

Wright State University

Other

Registry information

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Jul 5, 2024
Registry last updated
May 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.